HomeNewsBusinessEarningsBiocon Sept qtr PAT seen down 14% at Rs 77cr: Dolat Capital

Biocon Sept qtr PAT seen down 14% at Rs 77cr: Dolat Capital

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Biocon September quarter net sales are expected to go down by 30.1% at Rs 475 crore, year-on-year, (YoY) basis.

October 11, 2011 / 13:48 IST
Story continues below Advertisement

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, Biocon September quarter net sales are expected to go down by 30.1% at Rs 475 crore, year-on-year, (YoY) basis. Notably, the estimated sales in Sep

first published: Oct 11, 2011 12:09 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!